Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria.
Rossig C, Juergens H, Schrappe M, Moericke A, Henze G, von Stackelberg A, Reinhardt D, Burkhardt B, Woessmann W, Zimmermann M, Gadner H, Mann G, Schellong G, Mauz-Koerholz C, Dirksen U, Bielack S, Berthold F, Graf N, Rutkowski S, Calaminus G, Kaatsch P, Creutzig U. Rossig C, et al. Among authors: von stackelberg a. Pediatr Blood Cancer. 2013 Oct;60(10):1574-81. doi: 10.1002/pbc.24598. Epub 2013 Jun 5. Pediatr Blood Cancer. 2013. PMID: 23737479 Review.
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Willer A, Gerss J, König T, Franke D, Kühnel HJ, Henze G, von Stackelberg A, Möricke A, Schrappe M, Boos J, Lanvers-Kaminsky C. Willer A, et al. Among authors: von stackelberg a. Blood. 2011 Nov 24;118(22):5774-82. doi: 10.1182/blood-2011-07-367904. Epub 2011 Sep 22. Blood. 2011. PMID: 21940824 Free article.
Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004.
Creutzig U, Dworzak M, Zimmermann M, Bourquin JP, Gruhn B, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, von Stackelberg A, Stray J, Reinhardt D. Creutzig U, et al. Among authors: von neuhoff c, von stackelberg a. Klin Padiatr. 2015 May;227(3):116-22. doi: 10.1055/s-0035-1548816. Epub 2015 May 18. Klin Padiatr. 2015. PMID: 25985446 Clinical Trial.
Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004.
Rasche M, von Neuhoff C, Dworzak M, Bourquin JP, Bradtke J, Göhring G, Escherich G, Fleischhack G, Graf N, Gruhn B, Haas OA, Klingebiel T, Kremens B, Lehrnbecher T, von Stackelberg A, Tchinda J, Zemanova Z, Thiede C, von Neuhoff N, Zimmermann M, Creutzig U, Reinhardt D. Rasche M, et al. Among authors: von neuhoff n, von neuhoff c, von stackelberg a. Leukemia. 2017 Dec;31(12):2807-2814. doi: 10.1038/leu.2017.121. Epub 2017 Apr 25. Leukemia. 2017. PMID: 28443606 Free PMC article.
Phase II study of gemcitabine in children with relapsed leukemia.
Wagner-Bohn A, Henze G, von Stackelberg A, Boos J. Wagner-Bohn A, et al. Among authors: von stackelberg a. Pediatr Blood Cancer. 2006 Feb;46(2):262. doi: 10.1002/pbc.20632. Pediatr Blood Cancer. 2006. PMID: 16331664 Clinical Trial. No abstract available.
Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report.
Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Kremens B, Lehrnbecher T, von Neuhoff C, Sander A, von Stackelberg A, Schmid I, Starý J, Steinbach D, Vormoor J, Reinhardt D. Creutzig U, et al. Among authors: von neuhoff c, von stackelberg a. Leukemia. 2012 Apr;26(4):654-61. doi: 10.1038/leu.2011.267. Epub 2011 Oct 4. Leukemia. 2012. PMID: 21968880
Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.
Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, Bourquin JP, Klingebiel T, Borkhardt A, Cario G, Alten J, Escherich G, Astrahantseff K, Seeger K, Henze G, von Stackelberg A. Eckert C, et al. Among authors: von stackelberg a. Leukemia. 2015 Aug;29(8):1648-55. doi: 10.1038/leu.2015.59. Epub 2015 Mar 9. Leukemia. 2015. PMID: 25748682
KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia.
Malinowska-Ozdowy K, Frech C, Schönegger A, Eckert C, Cazzaniga G, Stanulla M, zur Stadt U, Mecklenbräuker A, Schuster M, Kneidinger D, von Stackelberg A, Locatelli F, Schrappe M, Horstmann MA, Attarbaschi A, Bock C, Mann G, Haas OA, Panzer-Grümayer R. Malinowska-Ozdowy K, et al. Among authors: von stackelberg a. Leukemia. 2015 Aug;29(8):1656-67. doi: 10.1038/leu.2015.107. Epub 2015 Apr 28. Leukemia. 2015. PMID: 25917266 Free PMC article.
144 results